Attovia Therapeutics

Attovia Therapeutics is a clinical-stage biopharmaceutical company in San Carlos, California, founded in 2022 and developing next-generation precision biologics for immune-mediated diseases. Its proprietary ATTOBODY platform is a modular protein design technology built on biparatopic nanobody scaffolds, used to engineer multispecific biologics that inhibit two, three, or four disease-driving pathways from a single molecule while targeting improved selectivity, stability, and less frequent dosing than existing therapies. The lead program ATTO-1310 is an anti-IL-31 candidate in Phase 1 for chronic pruritus and high-itch atopic dermatitis; ATTO-2306 (IL-31 x IL-13) and ATTO-1091 (TL1A x IL-23p19 x integrin alpha-4-beta-7, for inflammatory bowel disease) are in IND-enabling studies, alongside discovery-stage programs in rheumatology, IBD, and respiratory disease. The company raised a $105M Series B led by Goldman Sachs Alternatives and listed on Nasdaq as ATTO in August 2026, raising $289M. Attovia publishes no public API, developer portal, SDK, or machine-readable specification — its product is therapeutics, not software.

Attovia Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Life Sciences, and Immunology.

Attovia Therapeutics’ developer surface includes support and 6 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyBiopharmaceuticalLife SciencesImmunologyTherapeuticsDrug DiscoveryClinical Stage

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 11.8/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.7 / 17

Commercial Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/attovia: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 1

The organization behind the API

Website

Website

Other 1

Properties that don't map to a standard resource type

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: attovia
name: Attovia Therapeutics
description: Attovia Therapeutics is a clinical-stage biopharmaceutical company in San Carlos, California, founded in 2022
  and developing next-generation precision biologics for immune-mediated diseases. Its proprietary ATTOBODY platform is a
  modular protein design technology built on biparatopic nanobody scaffolds, used to engineer multispecific biologics that
  inhibit two, three, or four disease-driving pathways from a single molecule while targeting improved selectivity, stability,
  and less frequent dosing than existing therapies. The lead program ATTO-1310 is an anti-IL-31 candidate in Phase 1 for chronic
  pruritus and high-itch atopic dermatitis; ATTO-2306 (IL-31 x IL-13) and ATTO-1091 (TL1A x IL-23p19 x integrin alpha-4-beta-7,
  for inflammatory bowel disease) are in IND-enabling studies, alongside discovery-stage programs in rheumatology, IBD, and
  respiratory disease. The company raised a $105M Series B led by Goldman Sachs Alternatives and listed on Nasdaq as ATTO
  in August 2026, raising $289M. Attovia publishes no public API, developer portal, SDK, or machine-readable specification
  — its product is therapeutics, not software.
image: https://www.attovia.com/wp-content/uploads/2023/09/Attovia-logo.svg
url: https://raw.githubusercontent.com/api-evangelist/attovia/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: no-api-surface
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Life Sciences
- Immunology
- Therapeutics
- Drug Discovery
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/attovia-domain-security.yml
- type: LLMsTxt
  url: llms/attovia-llms.txt
- type: Website
  url: https://www.attovia.com/
- type: TermsOfService
  url: https://www.attovia.com/terms-of-use/
- type: PrivacyPolicy
  url: https://www.attovia.com/privacy-policy/
- type: Support
  url: https://www.attovia.com/contact-us/
- type: SecondaryMarket
  url: https://forgeglobal.com/attovia_stock/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Attovia is a clinical-stage biopharmaceutical company whose product is multispecific antibody therapeutics, not
    software — its entire public web presence is a ten-page WordPress corporate site (platform, pipeline, team, careers, contact,
    legal) with no developer section, and api/developers/developer/docs.attovia.com do not resolve in DNS.
  evidence:
  - url: https://www.attovia.com/openapi.json
    status: 404
  - url: https://www.attovia.com/.well-known/agent-card.json
    status: 404
  - url: https://www.attovia.com/llms.txt
    status: 404
  - url: https://www.attovia.com/page-sitemap.xml
    status: 200
  checked: '2026-08-06'